When was Amprion founded?

Amprion was founded in 2006 and raised its 1st funding round 6 years after it was founded.

Where is Amprion located?

Amprion is headquartered in Houston, United States. It is registered at San Francisco, California.

How many employees does Amprion have?

As of Sep 30, 2026, the latest employee count at Amprion is 38.

Is Amprion a funded company?

Amprion is a funded company, having raised a total of $11.8M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 16, 2012.

When was the latest funding round of Amprion?

Amprion's latest funding was a $***** Series B round on Jul 08, 2026, with participation from 1 investor.

Where does Amprion rank among its competitors?

Amprion ranks 2nd amongst 56 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Amprion, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Amprion?

Amprion's top competitors include Octave Bioscience, PeopleBio R&D and Nanostics. Among them, Amprion secured the most recent funding round in July, 2026.

Amprion - 2026 Company Profile, Team, Funding & Competitors

Amprion is a series B company based in Houston (United States), founded in 2006 by Claudio Soto. It operates as a Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology. Amprion has raised $11.8M in funding from Formationve. The company has 56 active competitors, including 13 funded and 6 that have exited. Its top competitors include companies like Octave Bioscience, PeopleBio R&D and Nanostics.

Company Details

Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology. They offer innovative diagnostic solutions for neurodegenerative disorders, providing clinicians and biopharma companies with tools for accurate and early detection. Their core technology, SAAmplify, detects misfolded α-synuclein, aiding in the diagnosis of diseases like Parkinson’s, Lewy body dementia, and Alzheimer’s. This technology moves beyond symptom-based diagnosis, offering biological clarity for improved treatment decisions. They provide resources, clinical studies, and testing services to support patients, clinicians, and researchers. Their mission is to impact lives by identifying diseases early, minimizing brain damage. They offer a test for detecting synucleinopathies before symptoms progress, identifying mixed pathologies for improved care. They partner with biopharma to accelerate clinical trials, stratify patients, and monitor treatment efficacy. They provide access to expertise and technology for advancing neurodegenerative science.

Website: www.ampriondx.com/
Email ID: *****@ampriondx.com
Registered Address: San Francisco, California

Key Metrics

Founded Year

2006

Location

Houston, United States

Stage

Series B

Total Funding

$11.8M in 9 rounds

Latest Funding Round

Series B, Jul 08, 2026, $*****

Investors

Formationve & 4 more

Ranked

2^nd among 56 active competitors

Employee Count

38 as on Sep 30, 2026

Similar Companies

Octave Bioscience & 70 more

View Amprion's full profile

Amprion is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Amprion Inc. CIN: 32034159650 , United States, Active	Nov 15, 2007	-	-	-
Amprion Inc CIN: 261195143 , United Kingdom, Active		-	17 (As on Dec 31, 2022)
AMPRION INC CIN: 261195143 , United States, Active	Dec 31, 1999	-	30 (As on Dec 31, 2024)	-

Amprion has raised a total funding of $11.8M over 9 rounds. Its first funding round was on May 16, 2012. Its latest funding round was a Series B round on Jul 08, 2026 for $*****. 1 investor participated in its latest round. Amprion has 5 institutional investors.

Here is the list of recent funding rounds of Amprion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 08, 2026	1225080	Series B	3202871	4709589	2724746	4464387
Oct 10, 2024	2611317	Series B	7280514	9655571	1964467	Lilly
Sep 12, 2024	3589236	Grant (prize money)	8179821	2821575	8823313	ALS Network

Access funding benchmarks and valuations. Sign up today!

View details of Amprion's funding rounds and investors

The founders of Amprion is Claudio Soto.

Here are the details of Amprion's key team members:

Claudio Soto: Co-Founder & CSO, Director of Amprion.

View details of Amprion's Founder profiles and Board Members

Amprion's employee count trend

Amprion has 38 employees as of Sep 26. Here is Amprion's employee count trend over the years:

Uncover Amprion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amprion include Octave Bioscience, PeopleBio R&D and Nanostics. Here is the list of Top 10 competitors of Amprion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$124M	Novartis, BVF & 14 others	65/100
2nd	Amprion 2006, Houston (United States), Series B	Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology	$11.8M	Lilly, Decathlon Capital Partners & 3 others	56/100
3rd	PeopleBio R&D 2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	DT&Investment, GNTech Venture Capital & 12 others	48/100
4th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100
5th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Maven Capital Partners, Northwest Fund & 22 others	38/100
6th	Alseres Pharmaceuticals 1972, Auburndale (United States), Public	Therapeutic and diagnostic products for disorders in the central nervous system (CNS)	$4M	Ingalls and Snyder	35/100
7th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	35/100
8th	Durin Life Sciences 2010, United States, Acquired	Early disease detection blood tests for Alzheimer's and Parkinson's	$5.5M	-	34/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	32/100
10th	Gene Solutions 2006, Charlottesville (United States), Series A	Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases	$6.33M	-	32/100